ORGANOGENESIS HOLDINGS INC. Operating Lease, Expense
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Operating Lease, Expense of $6.51 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-01
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for the quarter ending 2020-12-31 was $1.54M, a 24.23% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for the quarter ending 2020-09-30 was $1.62M, a 8.27% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for the quarter ending 2020-06-30 was $1.84M, a 14.60% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for the quarter ending 2020-03-31 was $1.51M, a 9.39% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for fiscal 2020 was $6.51M, a 4.46% increase from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for fiscal 2019 was $6.23M, a 34.64% increase from fiscal 2018.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for fiscal 2018 was $4.63M, a 10.06% increase from fiscal 2017.
- ORGANOGENESIS HOLDINGS INC. operating lease, expense for fiscal 2017 was $4.21M, a 142.36% increase from fiscal 2016.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.16M derived: sum of 2 quarters · filed 2022-03-01 | $5.00M derived: sum of 3 quarters · filed 2022-03-01 | $6.51M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $1.62M 10-Q · filed 2021-11-09 | $3.46M derived: sum of 2 quarters · filed 2021-11-09 | $4.97M 10-Q · filed 2021-11-09 | $6.21M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $1.84M 10-Q · filed 2021-08-09 | $3.35M 10-Q · filed 2021-08-09 | $4.59M derived: sum of 3 quarters · filed 2022-03-01 | $6.36M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $1.51M 10-Q · filed 2021-05-11 | $2.75M derived: sum of 2 quarters · filed 2022-03-01 | $4.52M derived: sum of 3 quarters · filed 2022-03-01 | $6.12M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.00M derived: sum of 2 quarters · filed 2022-03-01 | $4.61M derived: sum of 3 quarters · filed 2022-03-01 | $6.23M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $1.77M 10-Q · filed 2020-11-09 | $3.37M derived: sum of 2 quarters · filed 2020-11-09 | $4.99M 10-Q · filed 2020-11-09 | $5.75M derived: sum of 4 quarters · filed 2021-03-16 | ||
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-10 | $2.92M 10-Q · filed 2020-08-10 | $3.98M derived: sum of 3 quarters · filed 2021-03-16 | $5.20M derived: sum of 4 quarters · filed 2021-03-16 | ||
| 2019-03-31 | $1.38M 10-Q · filed 2020-05-11 | $881.00K 10-Q · filed 2019-05-10 | $2.38M derived: sum of 2 quarters · filed 2021-03-16 | $3.60M derived: sum of 3 quarters · filed 2021-03-16 | $4.70M derived: sum of 4 quarters · filed 2021-03-16 | |
| 2018-12-31 | $998.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.22M derived: sum of 2 quarters · filed 2021-03-16 | $3.32M derived: sum of 3 quarters · filed 2021-03-16 | $4.63M 10-K · filed 2021-03-16 | $2.83M 10-K · filed 2019-03-18 | |
| 2018-09-30 | $1.22M 10-Q · filed 2019-11-12 | $2.32M derived: sum of 2 quarters · filed 2019-11-12 | $3.63M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $1.10M 10-Q · filed 2019-08-09 | $2.15M 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | $660.00K 10-Q · filed 2019-05-10 | |||||
| 2017-12-31 | $4.21M 10-K · filed 2020-03-09 | $2.28M 10-K · filed 2019-03-18 | ||||
| 2016-12-31 | $1.74M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |